Shots:

• The P-III (CLEAR-1) trial assesses picankibart's (200mg, Q4W at wk.0, 4 & 8 followed by 200mg/100mg, Q12W) safety & efficacy vs PBO to treat moderate to severe plaque psoriasis patients (n=500)
• Study met the co-1EPs, depicting PASI 90 attained by 80.3% vs 2.0% & sPGA 0/1 attained by 93.5% vs 13.1% at wk.16, sustained for wk.52. Picankibart (200mg, Q12W) showed PASI 90 & sPGA 0/1 in 84.9% & 85.9% of patients, respectively, at wk.52
• The 2EPs were also met for both picankibart groups, incl. the proportions attaining PASI 75, PASI 100, sPGA score of 0 & DLQI score of 0/1 at wk.16. The drug was superior in all these measures, with improvements sustained for wk.52. IND submission to the NMPA is planned for the same indication

Ref: Innovent | Image: Innovent

Related News:- Innovent’s Picankibart (IBI112) Meet its Primary Endpoint in the P-II (CIBI112A201) Study for the Treatment of Plaque Psoriasis

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com